|
KMID : 0390219990100010046
|
|
Journal of Clinical Otolaryngology, Head and Neck Surgery
1999 Volume.10 No. 1 p.46 ~ p.52
|
|
|
Clinical Evaluation of Livostin®(Levocabastine) in the Treatment of Perennial Allergic Rhinitis(Open Single Center Clinical Trial)
|
|
조진희/Jin Hee Cho
이동희/권용식/조주은/윤희로/서병도/Dong Hee Lee/Yong Sig Kwun/Ju Eun Cho/He Ro Yoon/Byung Do Suh
|
|
|
Abstract
|
|
|
Background & Objectives : The new Hl-receptor antagonist Livostin®
(Levocabastine) is one of the most potent antihistamine available. Its effects also
are known to be very specific, not displaying other systemic side efficacy. And it
protects against allergen-induced nasal symptoms. This study was carried out to
evaluate the efficacy of Livostin®(Levocabastine) in the treatment of
allergic rhinitis. Also this study was one of clinical trials for medications which have
been used for allergic rhinitis. Subjects & Methods : In our clinical study, trials have
been performed with Livostin®(Levocabastine) nasal spray in 20 patients
with allergic rhinitis at a dose of two puffs per nostril twice a day. The patient's and
the investigator's evaluations of nasal symptoms were assessed before intranasal
application, 1 week, and 2 weeks after intranasal application of Livostin®
(Levocabastine). Results : Both the patient's and the investigator's evaluation of nasal
symptoms showed significant improvement's after intranasal application of Livostin®
(Levocabastine)(p<0.05, respectively). There was no side effect during follow-up periods.
The global evaluation showed that 60% of Livostin®(Levocabastine)- treated
patients considered therapeutic to be excellent or good. Conclusion : It was suggested that
Livostin®(Levocabastine) might be effective and safe for the treatment
of perennial allergic rhinitis.
|
|
|
KEYWORD
|
|
|
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|